Clin2Atlas
AtlasOther conditionsSkin and subcutaneous diseases

Psoriasis

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251990 — Halobetasol propionate approved (FDA)1993 — Calcipotriene approved (FDA)1996 — Acitretin approved (FDA)1997 — Tazarotene approved (FDA)1998 — Leflunomide approved (FDA)1998 — Infliximab approved (FDA)1998 — Etanercept approved (FDA)2000 — Isopropyl alcohol approved (FDA)2002 — Adalimumab approved (FDA)2003 — Efalizumab approved (FDA)2006 — Zinc oxide approved (FDA)2006 — Abatacept approved (FDA)2008 — Certolizumab pegol approved (FDA)2009 — Golimumab approved (FDA)2009 — Ustekinumab approved (FDA)2010 — Roflumilast approved (FDA)2012 — Tofacitinib approved (FDA)2013 — Dimethyl fumarate approved (FDA)2014 — Apremilast approved (FDA)2015 — Secukinumab approved (FDA)2016 — Ixekizumab approved (FDA)2017 — Guselkumab approved (FDA)2017 — Brodalumab approved (FDA)2018 — Tildrakizumab approved (FDA)2019 — Risankizumab approved (FDA)2021 — Bimekizumab approved (FDA)2022 — Cravacitinib approved (FDA)2022 — Spesolimab approved (FDA)2022 — Tapinarof approved (FDA)
1990: Drug approval — Halobetasol propionate approved (FDA). 1993: Drug approval — Calcipotriene approved (FDA). 1996: Drug approval — Acitretin approved (FDA). 1997: Drug approval — Tazarotene approved (FDA). 1998: Drug approval — Leflunomide approved (FDA). 1998: Drug approval — Infliximab approved (FDA). 1998: Drug approval — Etanercept approved (FDA). 2000: Drug approval — Isopropyl alcohol approved (FDA). 2002: Drug approval — Adalimumab approved (FDA). 2003: Drug approval — Efalizumab approved (FDA). 2006: Drug approval — Zinc oxide approved (FDA). 2006: Drug approval — Abatacept approved (FDA). 2008: Drug approval — Certolizumab pegol approved (FDA). 2009: Drug approval — Golimumab approved (FDA). 2009: Drug approval — Ustekinumab approved (FDA). 2010: Drug approval — Roflumilast approved (FDA). 2012: Drug approval — Tofacitinib approved (FDA). 2013: Drug approval — Dimethyl fumarate approved (FDA). 2014: Drug approval — Apremilast approved (FDA). 2015: Drug approval — Secukinumab approved (FDA). 2016: Drug approval — Ixekizumab approved (FDA). 2017: Drug approval — Guselkumab approved (FDA). 2017: Drug approval — Brodalumab approved (FDA). 2018: Drug approval — Tildrakizumab approved (FDA). 2019: Drug approval — Risankizumab approved (FDA). 2021: Drug approval — Bimekizumab approved (FDA). 2022: Drug approval — Cravacitinib approved (FDA). 2022: Drug approval — Spesolimab approved (FDA). 2022: Drug approval — Tapinarof approved (FDA)

What's being tested now

2002: 1 trials started2007: 1 trials started2008: 1 trials started2011: 1 trials started2012: 2 trials started2013: 4 trials started2014: 1 trials started2015: 3 trials started2017: 5 trials started2018: 2 trials started2019: 13 trials started2020: 10 trials started2021: 22 trials started2022: 17 trials started2023: 24 trials started2024: 39 trials started2025: 90 trials started2026: 84 trials started20102020202690

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 293 active Psoriasis trials on Clin2 →

Related

ScabiesFungal skin diseasesViral skin diseasesAcne vulgarisAlopecia areataPruritusUrticariaDecubitus ulcerOther skin and subcutaneous diseases

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.